Memantine Ameliorates Migraine Headache

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Migraine treatment remains a challenge, with many patients lacking effective and safe options.
• A need exists for novel therapeutic agents to manage migraine frequency and severity.

Purpose of the Study:

• To evaluate the efficacy and safety of memantine as a treatment for migraine.
• To assess memantine's impact on migraine frequency, responder rates, and medication use.

Main Methods:

• A 24-week, randomized, placebo-controlled, double-blind study in India.
• Adult patients with 3-12 migraine headaches were randomized to receive memantine (10 mg/day) or placebo.
• Key outcomes included monthly migraine frequency, 50% responder rate, rescue medication use, and adverse events.

Main Results:

• Memantine significantly reduced migraine frequency (2.57 vs 5.07 per 4 weeks, P=0.003) and rescue medication use (0.75 vs 3.72, P=0.0001).
• The 50% responder rate was higher in the memantine group (85.7%) compared to placebo (51.7%, P=0.005).
• Mild adverse events were infrequent and comparable between groups; no severe events or deaths occurred.

Conclusions:

• Memantine (10 mg oral, once daily) demonstrates significant efficacy in reducing migraine frequency and improving patient outcomes.
• The drug is well-tolerated and safe for migraine patients.
• Memantine represents a promising new therapeutic option for migraine management.